AstraZeneca and Oracle sign a non-binding AI collaboration, with a first programme on hypertension care and trial recruitment in Abu Dhabi
AstraZeneca and Oracle Health and Life Sciences announced a global AI collaboration combining AstraZeneca's clinical development and regulatory expertise with Oracle's real-world data, cloud infrastructure and AI-enabled clinical capabilities, aiming to speed clinical research and bring evidence into care workflows. The stated early areas include clinical trial recruitment, earlier diagnosis, drug-safety monitoring and real-world evidence across a medicine's lifecycle, spanning oncology, cardiovascular, renal and metabolic, respiratory and immunology, and rare disease. The first programme focuses on hypertension care and clinical research in Abu Dhabi with healthcare company M42; the companies signed a non-binding term sheet and disclosed no financials.